(YMAB) – Company Press Releases
-
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
-
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
-
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
-
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
-
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
-
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
-
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
-
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
-
Y-mAbs Announces Publication in Cancers
-
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
-
Y-mAbs to Participate at Upcoming Investor Conferences in September
-
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
-
Y-mAbs to Participate at Upcoming Investor Conferences
-
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
-
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
-
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
-
Y-mAbs Announces Presentation of Naxitamab data at AACR
-
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
-
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
-
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
-
YMAB FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securitie
-
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
-
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
YMAB LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
-
YMAB LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
-
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
-
Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
-
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
-
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe
-
Y-mAbs Announces Pipeline Update
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
-
Y-mAbs to Host Annual Research and Development Day in New York
-
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
-
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Back to YMAB Stock Lookup
